Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 5/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
| ▸ | GLB1 | P16278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12517417 | 0.91 | GNAI3 (0.35) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL893205 | 0.88 | GNAI3 (0.33) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL2369632 | 0.86 | GNAI3 (0.34) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL870983 | 0.85 | GNAI3 (0.38) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL27907857 | 0.85 | S1PR4 (0.35) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL12910969 | 0.83 | ALDH1A1 (0.31) | GNAI3GNAO1GNAI1 | |
| SCHEMBL8532351 | 0.82 | GNAI3 (0.41) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL9491106 | 0.82 | GNAI3 (0.41) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL26668878 | 0.82 | GNAI3 (0.41) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL6298166 | 0.82 | S1PR4 (0.31) | S1PR4S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210828-A1 | STERICALLY HINDERED AMINES | BASF SE (DE) | 2015-07-30 | — | — | US | disclosed |
| US-9045430-B2 | Sterically hindered amines | BASF SE (DE) | 2015-06-02 | — | — | US | disclosed |
| EP-2542526-B1 | Sterically hindered amines | BASF SE (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20130059952-A1 | PHOSPHO-SUBSTITUTED ALKOXYAMINE COMPOUNDS | BASF SE (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059952-A1 | PHOSPHO-SUBSTITUTED ALKOXYAMINE COMPOUNDS | BASF SE (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130041076-A1 | STERICALLY HINDERED AMINES | BASF SE (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2542526-A1 | STERICALLY HINDERED AMINES | BASF SE (DE) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107513-A1 | STERICALLY HINDERED AMINES | BASF SE (DE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011086114-A1 | PHOSPHO-SUBSTITUTED ALKOXYAMINE COMPOUNDS | BASF SE (DE) | 2011-07-21 | — | — | WO | disclosed |
| EP-2035381-B1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2008003602-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | CIBA HOLDING INC. (CH) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210828-A1 | STERICALLY HINDERED AMINES | CCNA1, C5, H1-0 | GNAI3 3844/4885GNAO1 1584/4885GNAI1 2858/4885 |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | PPOX, CBR1, CBR3 | GNAI3 3289/4885GNAO1 1257/4885GNAI1 3270/4885 |
| US-20130059952-A1 | PHOSPHO-SUBSTITUTED ALKOXYAMINE COMPOUNDS | PFAS, PHOSPHO1, PIK3CA | GNAI3 2148/4885GNAO1 1873/4885GNAI1 2771/4885 |
| US-20130041076-A1 | STERICALLY HINDERED AMINES | CCNA1, C5, H1-0 | GNAI3 3844/4885GNAO1 1584/4885GNAI1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.